Sheffield Children's Hospital, Sheffield, UK.
Br J Haematol. 2014 Aug;166(3):421-4. doi: 10.1111/bjh.12882. Epub 2014 Apr 8.
We investigated the outcome for children and young people with Early T-precursor acute lymphoblastic leukaemia (ETP-ALL), a recently described poor prognosis sub-group of T-ALL, treated on a contemporary protocol, UKALL 2003. After a median follow-up of 4 years and 10 months, the ETP sub-group, representing 16% of T-ALL patients, had non-significantly inferior 5-year event-free survival (76·7% vs. 84·6%, P = 0·2) and overall survival (82·4% vs. 90·9%, P = 0·1), and a higher relapse rate (18·6% vs. 9·6%, P = 0·1) compared to typical T-ALL. ETP-ALL has an intermediate risk outcome, which does not warrant experimental treatment or first remission allogeneic transplant for the group universally.
我们研究了接受当代方案 UKALL 2003 治疗的早前期 T 细胞前体急性淋巴细胞白血病（ETP-ALL）患儿和青少年的结局，ETP-ALL 是 T 细胞 ALL 中近期描述的预后不良亚组。中位随访 4 年 10 个月后，占 T-ALL 患者 16%的 ETP 亚组的 5 年无事件生存率（76.7% vs. 84.6%，P=0.2）和总生存率（82.4% vs. 90.9%，P=0.1）非显著降低，与典型 T-ALL 相比，复发率更高（18.6% vs. 9.6%，P=0.1）。ETP-ALL 的预后为中等风险，这并不意味着该组普遍需要进行实验性治疗或首次缓解时进行异基因移植。
